Systems biology at its best tightly couples experimental biology with modeling methodologies. Experimental later keep the theories generated through computation realistic;carefully constructed mathematical models 'can generate new testable hypotheses. Achieving this balance, however, demands interdisciplinary collaborations such as set up in the CHAIN Center, and the experience and skills as available in this Core. The Systems Biology and Integrative Networks Core (SB-INC, aka Systems Biology Core) is to enable genome-scale technology and state-of-the-art bioinformatics tools for the study of neuroAIDS. CHAIN researchers can to collect or analyze genome-scale data though active collaboration with members of the SB-INC Available experimental platforms include RNA-seq, chlP-seq, and protein interaction screens via Y2H and M2H. Available bioinformatic technologies include clustering and classification of gene expression or metabolomic profiles, integration of molecular profiles with molecular networks, and identification of network-based biomarkers. SB-INC will also support research and development centered on combinatorial transcriptional interaction maps. We will map the transcripfional networks underlying developmental processes of high relevance to neuroAIDS, including neuronal degeneration and protection and activation and differentiation of macrophages. Through these methods we will develop network-based biomarkers to predict the potential for development of neuroAIDS, the presence of neuroAIDS, and response to treatment.

Public Health Relevance

Systems biology approaches are ideal for the analysis of complex systems such as chronic HIV infection and the brain. This Core provides world-class resources , skills, and experimental approaches for the study neuroAIDS.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Center Core Grants (P30)
Project #
5P30MH062261-13
Application #
8436271
Study Section
Special Emphasis Panel (ZMH1-ERB-M)
Project Start
Project End
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
13
Fiscal Year
2013
Total Cost
$196,083
Indirect Cost
Name
University of Nebraska Medical Center
Department
Type
DUNS #
168559177
City
Omaha
State
NE
Country
United States
Zip Code
68198
Guijas, Carlos; Montenegro-Burke, J Rafael; Warth, Benedikt et al. (2018) Metabolomics activity screening for identifying metabolites that modulate phenotype. Nat Biotechnol 36:316-320
Kevadiya, Bhavesh D; Woldstad, Christopher; Ottemann, Brendan M et al. (2018) Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution. Theranostics 8:256-276
McMillan, JoEllyn; Szlachetka, Adam; Slack, Lara et al. (2018) Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques. Antimicrob Agents Chemother 62:
Sillman, Brady; Woldstad, Christopher; Mcmillan, Joellyn et al. (2018) Neuropathogenesis of human immunodeficiency virus infection. Handb Clin Neurol 152:21-40
Dave, Rajnish S; Jain, Pooja; Byrareddy, Siddappa N (2018) Functional Meningeal Lymphatics and Cerebrospinal Fluid Outflow. J Neuroimmune Pharmacol 13:123-125
Dyavar, Shetty Ravi; Ye, Zhen; Byrareddy, Siddappa N et al. (2018) Normalization of cell associated antiretroviral drug concentrations with a novel RPP30 droplet digital PCR assay. Sci Rep 8:3626
Ottemann, Brendan M; Helmink, Austin J; Zhang, Wenting et al. (2018) Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities. Biomaterials 185:174-193
Brenza, Timothy M; Schlichtmann, Benjamin W; Bhargavan, Biju et al. (2018) Biodegradable polyanhydride-based nanomedicines for blood to brain drug delivery. J Biomed Mater Res A 106:2881-2890
Sathyanesan, Monica; Watt, Michael J; Haiar, Jacob M et al. (2018) Carbamoylated erythropoietin modulates cognitive outcomes of social defeat and differentially regulates gene expression in the dorsal and ventral hippocampus. Transl Psychiatry 8:113
Zhou, Tian; Su, Hang; Dash, Prasanta et al. (2018) Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials 151:53-65

Showing the most recent 10 out of 374 publications